Crosstalk between autophagy and metabolic regulation of cancer stem cells

Mouradi El Hout 1,2, Emma Cosialls 1,2, Maryam Mehrpour 1,2* and Ahmed Hamai 1,2*

Abstract
Cancer is now considered as a heterogeneous ecosystem in which tumor cells collaborate with each other and with host cells in their microenvironment. As circumstances change, the ecosystem evolves to ensure the survival and growth of the cancer cells. In this ecosystem, metabolism is not only a key player but also drives stemness. In this review, we first summarize our current understanding of how autophagy influences cancer stem cell phenotype. We emphasize metabolic pathways in cancer stem cells and discuss how autophagy-mediated regulation metabolism is involved in their maintenance and proliferation. We then provide an update on the role of metabolic reprogramming and plasticity in cancer stem cells. Finally, we discuss how metabolic pathways in cancer stem cells could be therapeutically targeted.

Keywords: Cancer stem cells, Autophagy, Metabolic heterogeneity, Lipid metabolism, Therapeutic target

Background
Cancer is a heterogeneous disease, and metabolic flexibility of tumors contributes to this heterogeneity. As circumstances change, the tumor ecosystem evolves to ensure the survival and growth of the cancer cells [1]. In this ecosystem, metabolism is a driver of stemness [2]. Cancer stem cells (CSCs) are a subset of cells within tumors that have the capacity to generate tumors and that exhibit self-renewal and differentiation properties. CSCs are resistant to cancer therapies and are a distinct population associated with metastasis and relapse.

Only a few studies have directly examined the metabolism of CSCs in large part due to difficulties in isolating this population. Currently, there are more than 40 established CSC markers; however, most are also present in human embryonic stem cells and/or adult stem cells from normal tissues and a consensus marker for the identification of CSCs still a matter of debate. We begin this review with a brief discussion of autophagy and CSCs, and we review recent data on CSC metabolism. Finally, we discuss how CSC metabolism could be a therapeutic target for treatment of cancer.

Autophagy in CSCs
Autophagy is a process necessary for normal cellular function involved in the tumor initiation, tumor interactions with neighboring cells in the tumor microenvironment, and cancer therapy. The role of autophagy in cancer is multifaceted: Autophagy promotes tumor cell survival by supplying recycled metabolites for growth, modulates mitochondrial function via mitophagy (the selective degradation of mitochondria), and functions in tumor cell migration and invasion via control of secretion of pro-migratory cytokines and focal adhesion turnover [3]. Also, several studies have demonstrated that autophagy plays a central role in the tumor microenvironment [3, 4]. For example, autophagy is induced in cancer-associated fibroblasts (CAFs) by their association with tumor cells, and this results in increased fibroblast production of amino acids, which are provided in a paracrine manner to tumor cells to sustain their growth [5]. Two important elements that influence metabolic reprogramming of tumors are their microenvironment and the distance to the vasculature [1, 4]. First, emerging evidence indicates the unexpected ability of malignant cells (both CSCs and non-CSCs) to supplement their metabolism with nutrients provided by neighboring cells with complementary metabolic activities, enhancing tumor cell survival and proliferative capacity [6–8]. Second, cancer cells located closer to the blood supply generate ATP via oxidative stress, and this induces glycolysis and autophagy in the surrounding catabolic...
stromal/cancer cells (again, in both CSCs and non-CSCs), which generate catabolites such as fatty acids, lactates, and ketones that in turn are taken up by anabolic cancer cells (both CSCs and non-CSCs) and used to fuel mitochondrial metabolism and ATP production. This is known as the reverse Warburg effect (Table 1). Parallel autophagic responses activated in distal and poorly oxygenated tumor areas provide catabolic intermediates to sustain anabolic demands and support cancer growth (Table 1).

Recent reviews have focused on the role of autophagy in tumor metabolism [4], anti-tumor immunity [3], and cancer metastasis and cancer therapy [11]. Here, we briefly discuss more recently reported roles for autophagy in CSCs. Autophagy appears to be necessary for the maintenance of stemness in both normal tissue stem cells [12] and CSCs [13, 14] in diverse cancer types including breast, pancreatic, bladder, and colorectal cancers, chronic myeloid leukemia, and glioblastoma (for review see [8]). The survival and quiescence of normal tissue stem cells is dependent on autophagy, and autophagy has also been reported to promote pluripotency. In CSCs, autophagy promotes expression of stem cell markers such as CD44 as well as expression of mesenchymal markers such as vimentin [13]. Autophagy also promotes spheroid formation in vivo tumorigenesis consistent with a critical role in maintaining CSCs [14]. Further, the inhibition of autophagy limits tumor dormancy and promotes outgrowth of metastases [15]. Key transcription factors have been linked to the induction of autophagy and the stem cell state including Forkhead box 3A (FOXO3A), which induces expression of autophagy genes in stem cells and is itself turned over by autophagy. Other transcription factors, including the core stemness factors sex determining region Y-box (SOX2) and Nanog Homeobox (NANOG), have also been linked to autophagy induction [16]. Also, SOX2 and STAT3 have been shown to modulate autophagy genes and to determine the stemness of CSCs.

Mitophagy is emerging as a key in the control of normal tissue stem cell homeostasis. Mitophagy functions to control mitochondria quality and also regulates cellular metabolism. For example, removing damaged mitochondria, the main source of ROS, by mitophagy prevents senescence and limits ROS-induced genome damage. Limiting ROS damage is essential for maintenance of stemness. An essential role for mitophagy has reported during the glycolytic switch necessary for mouse developmental neurogenesis [12]. The turnover of mitochondria through mitophagy helps to maintain the stem cell state by limiting the capacity of the stem cells for oxidative phosphorylation (OXPHOS) and making the stem cells more dependent on glycolysis for energy demands. Inhibition of mitophagy suppresses CD44 expression and also promotes translocation of p53 to the nucleus, where it antagonizes expression of stem cell genes.

The high levels of autophagy observed in CSCs are associated with the maintenance of pluripotency, with resistance to chemotherapy, and with migration and invasion [3]. Autophagy allows CSCs to survive despite hypoxia and low levels of nutrients in the tumor microenvironment [17]. Missing is a comprehensive view of how these processes drive CSC fate, and few of the regulatory molecules involved have been identified. Readers interested in detailed discussion of autophagy processes in CSCs should see a recent review [8].

**CSCs are more glycolytic than other differentiated cancer cells**

A growing body of evidence suggests that the metabolism of CSC also differs from that of the bulk tumors. The importance of glucose for the maintenance and propagation of CSCs was first established in glioblastoma (GBM) [18] and then in other types of cancer including breast cancer, colon cancer, lung cancer, ovarian cancer, and osteosarcoma [2]. The side population cells with CSC characteristics avidly consume glucose and generate a significant amount of ATP and lactate [19]. In addition, in these cells the AKT Kinase pathway is activated by glucose and inhibition of glycolysis decreases the ability of these cells to form tumors in vivo. In ovarian cancer, the CD44+/MyD88+ CSCs depend only on glycolysis for their survival and are incapable of producing ATP by OXPHOS, resulting in autophagic death in the absence of glucose [20].

The metabolism of breast CSCs (BCSCs) grown as spheres is strongly associated with increased activities of key enzymes of anaerobic glucose fate such as pyruvate kinase isozyme M2 (PKM2), lactate dehydrogenase (LDH), and glucose-6-phosphate dehydrogenase (G6PDH). Consistent with this, BCSCs are highly sensitive to 2-deoxyglucose, a well-known inhibitor of glycolysis [21]. The overexpression of fructose-1,6- bisphosphatase (FBP1) and the increase of

---

**Table 1** Warburg and Reverse Warburg effects

| Aerobic glycolysis | or the Warburg effect, is a phenomenon in cancer cells that results in reorientation of metabolism to the glycolytic pathway and to conversion of pyruvate resulting from glycolysis into lactate even in the presence of oxygen. This metabolic reprogramming is a step in the process of tumorogenesis in many cancers. It is one of the best-described metabolic adaptations arising in cancer cells. It is now established, however, that malignant transformation is not based solely on the Warburg effect. Indeed, tumor cells produce a significant fraction of their ATP via oxidative phosphorylation (OXPHOS). Malignant cells adapt their energetic metabolism to the conditions of the microenvironment, in particular to the oxygenation conditions of the tumor, which has the consequence of creating intra-tumor metabolic heterogeneity (for additional information see [1, 5, 10]). The reverse Warburg effect is observed when anabolic epithelial cancer cells induce aerobic glycolysis in neighboring stromal fibroblasts or neighboring catabolic cancer cells. These catabolic cells epithelial cancer cells or cancer-associated fibroblasts secrete catabolites such as lactate, pyruvate (energy metabolites resulting from aerobic glycolysis), free fatty acids, and ketone bodies. Anabolic epithelial cancer cells take up these energy-rich metabolites and use them to fuel OXPHOS. This results in a higher proliferative capacity (see Fig. 1 and [1]). An absence of stromal Cav-1 may be a biomarker for the reverse Warburg effect. | }
ROS are accompanied by a significant reduction in the number of CD44<sup>hi</sup>/CD24<sup>lo</sup>/EpCAM<sup>+</sup> CSCs and the formation of spheres [22]. The increase of glucose uptake, glycolytic enzyme expression, lactate production, and ATP content in CSCs compared with their differentiated counterparts seems to be linked to a concomitant reduction in mitochondrial activity [18, 21] and also to maintenance of OXPHOS and beta-oxidation [23]. Mechanistic analysis demonstrated that decreased expression and activity of pyruvate dehydrogenase (PDH), a key regulator of oxidative phosphorylation, plays a critical role in promoting the pro-glycolytic phenotype of CSCs. Metabolic reprogramming via forced activation of PDH preferentially eliminates CSCs [24]. Tamada et al. showed that CD44, a marker of CSCs, acts as a metabolic modulator, activating glycolysis under hypoxic conditions and reducing glycolysis and antioxidant responses and enhancing mitochondrial production with associated increases in ROS. CD44 interacts with PKM2 in different cancer cell lines and inhibits its activity, correlating with the glycolytic phenotypes of p53-deficient cells [25]. A metabolic signature characteristic of colon cancer initiating cells has been associated with increased expression of genes and metabolites of the glycolytic pathway and the tricarboxylic acid cycle (TCA) [26].

CSCs rely on mitochondrial oxidative metabolism

In contrast to data linking the stem phenotype of cancer cells to glycolytic metabolism, emerging evidence indicates that CSCs have a preference for OXPHOS metabolism (Fig. 1). In both cases, mitochondrial function is essential for stemness, migration, and drug resistance of CSCs [27]. Compared to differentiated progeny, BCSCs consume more glucose, produce less lactate, and have higher ATP content. BCSCs are heterogeneous in their metabolic phenotypes and have metabolic states distinct from their differentiated progeny.

The increased mitochondrial mass in a distinct population of breast cancer cells is attributed to a stem-like phenotype and is associated with metastatic potential and chemotherapy resistance [28]. Despite a high rate of pentose phosphate pathway activity, which is not typical of cells that prefer OXPHOS over glycolysis, the CSCs isolated from patients with epithelial cancer overexpress genes associated with glucose uptake, OXPHOS, and fatty acid beta oxidation, indicating that in these cells pyruvate is preferentially directed toward the TCA cycle. Consistent with a metabolic OXPHOS profile, CSCs have higher mitochondrial ROS production and elevated membrane potential than normal cells and undergo apoptosis upon inhibition of the mitochondrial respiratory chain [29]. Consistent with previously reported data [30], CSCs display enhanced antioxidant defenses compared to their non-tumorigenic counterparts, and this may contribute to tumor resistance to therapy.

De Luca et al. recently reported that mitochondrial biogenesis is required for maintenance of stem-like properties [31]. The inhibition of mitochondrial biogenesis mediator PGC1α decreases the stem-like properties of BCSCs [31]. In pancreatic ductal adenocarcinoma (PDAC), the deadliest cancer in western countries, it has been shown that CSCs are OXPHOS-dependent, unlike non-CSCs that are glycolytic. In addition, suppression of MYC expression and increased expression of PGC1α are key determinants for the OXPHOS dependency of CSCs and their limited ability to switch to glycolysis during mitochondrial inhibition [32].

A recent study showed that Matcha green tea inhibits the propagation of BCSCs. Interestingly, metabolic phenotyping revealed that treatment with this compound suppresses both OXPHOS and glycolytic flux, shifting cancer cells toward a more quiescent metabolic state [33].

Other metabolic pathways involved in CSC maintenance and proliferation

Mevalonate metabolic pathway

A prominent role of the mevalonate metabolic pathway in regulating the self-renewal of basal/mesenchymal BCSCs has been demonstrated. Inhibition of this pathway with hydroxy-3-methylglutaryl CoA reductase blockers results in a reduction of BCSC proliferation independent of inhibition of cholesterol biosynthesis and of protein farnesylation. Notably, geranylgeranyl transferase I is crucial for BCSC maintenance. The effect of geranylgeranyl transferase I on the CSC subpopulation is mediated by inactivation of Ras homolog family member RHOA and increased accumulation of P27<sup>kip1</sup> in the nucleus [34]. Mesenchymal stem cells have been reported to shuttle mitochondria and/or mitochondrial DNA in leukemia, lung, and breast tumors and to consume the cysteine dimer cystine to provide leukemic cells with chemoprotective cysteine [7].

Hypoxia and redox homeostasis

Clinical data indicate that reduced oxygen availability, or hypoxia, observed in intratumoral regions activates hypoxia-inducible factors (HIFs). These master regulators of oxygen homeostasis also play key roles in the maintenance of BCSCs [35]. In response to intratumoral hypoxia or chemotherapy such as carboplatin or paclitaxel, the increased expression of HIF-1α and HIF-2α in BCSCs leads to increased expression of pluripotency factors such as Kruppel-like Factor 4 (KLF4), NANOG, octamer-binding transcription factor 4 (OCT4), and SOX2 [35]. HIF-1 coordinately regulates expression of genes encoding pyruvate dehydrogenase (PHGDH) and five downstream enzymes in the serine synthesis pathway and mitochondrial one-carbon (folate) cycle. Silencing of PHGDH expression leads to decreased NADPH levels, disturbed mitochondrial redox homeostasis, and increased apoptosis, which abrogate BCSC enrichment.
under hypoxic conditions. PHGDH-deficient cells are relatively weakly tumorigenic, and tumors that do form are deficient in BCSCs and thus have no metastatic capacity [36]. Human non-small cell lung cancer cells cultured in low folate conditions have enhanced CSC-like properties associated with elevated lactate release and medium acidification, suppressed expression of PDH, and elevated redox status as shown by NADH/NAD⁺ and NADPH/NADP⁺ ratios. These data are indicative of the metabolic reprogramming to aerobic glycolysis. Genetic and pharmacological inhibition of mechanistic target of rapamycin (mTOR) abrogates low folate-activated AKT-mTOR-HIF1-FOXO3a signaling and stemness-associated sonic hedgehog pathway activity, reverses the Warburg metabolic switch, and diminishes invasiveness of non-small cell lung cancer cells. These data suggest that lung CSCs may arise from a microenvironment low in folate through the activation of an AKT-mTOR-HIF1-FOXO3a signaling network, which promotes bioenergetic reprogramming to enhance CSC-

Fig. 1 The metabolic heterogeneity of cancer stem cells. Tumors are complex and dynamic structures encompassing populations of host cells (e.g., fibroblasts and immune cells) and cancer cells with different metabolic activities. These cells are affected in different ways by microenvironmental conditions and biological activities of other tumor cells. For example, cancer cells close to the vasculature show oxidative metabolism, whereas a shift toward a glycolytic metabolism is observed when glucose is present in cells residing in hypoxic areas. Despite metabolic heterogeneity, cancer cells cooperate to allow adoption to changes in conditions to ensure that metabolic requirements are met. Indeed, oxidative cancer cells, like proliferating cells, increase the consumption of glucose to produce ATP and generate biomass to support cell proliferation. The oxidative stress caused by rapidly proliferation of cancer cells induces glycolysis and autophagy/mitophagy in stromal cells and/or in glycolytic cancer cells leading to the release of high amounts of lactate, which fuels the metabolism of oxidative cancer cells. Key elements of lactate shuttles are the plasma membrane monocarboxylate transporters. MCT4 is involved in the export of lactate, and MCT1 and MCT2 are involved in the uptake of this catabolite. High levels of several factors including HIF-1α, NF-κB, TGF-β, and JNK/AP1 are associated with glycolytic phenotype. The metabolic status of a CSC depends on location. In actively growing regions of the tumor and in the presence of adequate levels of oxygen (normoxic conditions), CSCs rely on glycolytic and/or oxidative metabolism. Overexpression of HIF-1α in the hypoxic environment promotes upregulation of GLUT1, GLUT3, and glycolytic enzymes. In the metastatic niche, CSCs have increased utilization of extracellular catabolites. In nutrient-poor states, autophagy is activated to provide an alternative energy source. OXPHOS and the anabolic gluconeogenesis pathways control glucose homeostasis. Abbreviations: ATP, adenosine triphosphate; CSC, cancer stem cell; GLUT1/GLUT3, glucose transporter 1/3; HIF-1α, hypoxia-inducible factor 1α; HK2, hexokinase 2; JNK/AP1, c-Jun N-terminal kinases/activator protein 1; LDH, Lactate dehydrogenase; XMCT2/4, monocarboxylate transporter 2/4; NF-κB, nuclear factor-κB; OXPHOS, oxidative phosphorylation; PFKFB, phosphofructokinase/fructose bisphosphatase; PKM2, pyruvate kinase isozyme M2; TGF-β, transforming growth factor β.
like signatures and invasion and metastasis of lung cancers [37].

**NAD and nicotinamide phosphoribosyl transferase pathways are associated with tumorigenesis**

NAD is a cofactor essential for metabolism, energy production, DNA repair, maintenance of mitochondrial fitness, and signaling in many types of cancer cells. The biosynthesis of NAD occurs through both de novo and salvage pathways. NAD is primarily synthesized from nicotinamide, a process known as the NAD salvage pathway. Nicotinamide phosphoribosyl transferase (NAMPT) catalyzes the conversion of nicotinamide to nicotinamide mononucleotide (NMN), which is the rate-limiting step in the NAD salvage pathway. Thus, NAMPT is critical for NAD biosynthesis. Inhibition of NAMPT leads to depletion of NAD, which in turn inhibits ATP synthesis [38]. NAMPT is overexpressed in high-grade glioma and GBM tumors, and its levels correlate with tumor grade and prognosis. Ectopic overexpression of NAMPT in glioma cell lines is associated with the enrichment of glioblastoma CSC population and inhibition of NAMPT blocks in vivo tumorigenicity of glioblastoma CSCs. The self-renewal properties of the glioblastoma CSC population and radiation resistance in GBM are orchestrated by a NAD-dependent transcriptional network [39]. Along the same lines, Lucena-Cacace et al. also recently reported that NAMPT plays an important role in regulation of the CSC survival and proliferation in colon cancer tumors [40]. This phenotype is mediated by poly (ADP-ribose) polymerses (PARPs) and sirtuins (SIRTs).

Recently, Lucena-Cacace et al. raised the idea that NAMPT contributes to tumor dedifferentiation and, driven by NAD supply, is responsible for the epigenetic reprogramming observed in tumors [37]. This idea is supported by data reported by Jung et al. [41] who showed that mesenchymal glioblastoma stem cells (GSCs) contain higher levels of NAD and lower levels of nicotinamide, methionine, and S-adenosyl methionine (SAM) than do normal brain cells. The difference in NAD levels may be responsible for the differences in the self-renewal properties of glioblastoma CSCs. The self-renewal properties of glioblastoma CSC population and radiation resistance in GBM are orchestrated by a NAD-dependent transcriptional network [39]. Along the same lines, Lucena-Cacace et al. also recently reported that NAMPT plays an important role in regulation of the CSC survival and proliferation in colon cancer tumors [40]. This phenotype is mediated by poly (ADP-ribose) polymerses (PARPs) and sirtuins (SIRTs). The mechanisms underlying the NAD-dependent deacetylation by SIRT1 in the regulation of autophagy involve the activation or inhibition of multiple transcription factors, including FOXO3 and P53, and of ATG proteins such as ATG5, ATG12, ATG14, Beclin-1, Bcl-2/adenovirus E1B interacting protein 3 (Bnip3), and Microtubule-associated Protein 1 Light Chain 3 (LC3) [44]. However, further studies are required to confirm that NAD metabolism regulated by SIRT1 contributes to autophagy initiation in CSCs.

**Glutaminolysis**

Glutaminolysis is also essential for the proliferation and survival of epithelial CSCs largely because the ammonia molecules released from glutamine metabolism neutralize the excessive levels of protons (lactic acid) that result from the marked Warburg effect observed in these cells [45]. Epithelial CSCs preferentially rely on aerobic glycolysis for bioenergetics, display an active serine-one-carbon-glycine metabolism, and show an increased metabolic flexibility to utilize different carbon sources (such as fatty acids and glucose) that offsets the decreased diversion of glucose-derived carbons into the TCA cycle.

Recent studies have shed light on the role of iron metabolism in CSCs and suggest that specific targeting of iron metabolism in CSCs may improve the efficacy of cancer therapy. Readers interested in detailed discussion of iron metabolism in CSCs should see a recent review [46, 47].
Metabolic reprogramming and plasticity
It has been shown that the epithelial-mesenchymal transition (EMT) can endow cancer cells with stem cell-like properties and can cause a switch from an epithelial program to a motile mesenchymal phenotype [48]. However, in solid tumors, CSCs can arise independently of EMT. A comparative analysis using metabolomic and fluxomic approaches identified metabolic profiles that differentiate metastatic prostate epithelial CSCs from non-CSCs expressing a stable EMT signature. The epithelial CSCs (ECSCs) are distinguished by an enhanced Warburg effect and a greater carbon and energy source flexibility resulting from amino acid and fatty acid metabolism. ECSCs are also characterized by a critical dependence on the proton buffering capacity bestowed by glutamine metabolism. A metabolic gene signature for ECSCs has been correlated with tumor progression and metastasis in several cancer types [45].

The induction of EMT is associated with enhanced glycolysis and reduced mitochondrial activity. Mechanistic analysis demonstrated that this process is the result of the activation of cytochrome c oxidase [49] or from the suppression of fructose-1,6-bisphosphatase [22]. Furthermore, bioenergetic disorders resulting from the inhibition of citrate synthase or succinate dehydrogenase subunit B can contribute to the acquisition of an EMT phenotype [50]. Luo et al. reported that EMT-driven CSCs can metabolize alternative high-energy metabolites, the phenomenon known as reverse Warburg effect (Table 1) [51].

The comparison between mesenchymal-like CSCs (MCSC) and ECSCs revealed distinct metabolic pathways. MCSCs display enhanced glycolysis as well as reduced O2 consumption, reduced ROS production, more antioxidant capacity, and reduced mitochondrial mass and membrane potential compared to ECSCs [30, 52]. Recent work has divided GSCs into two subtypes with a mesenchymal GSC population as the more malignant subtype. Glycolytic and Aldehyde dehydrogenase 1A3 (ALDH1A3) activities are remarkably elevated in mesenchymal GSCs but not in proneural GSCs. Moreover, irradiation of proneural GSCs results in an up-regulation of mesenchymal-associated markers and a down-regulation of proneural-associated markers, and this effect is attenuated by inhibition of ALDH1A3 activity. For the high-grade glioma patients with the mesenchymal signature, inhibition of ALDH1A3-mediated pathways is thus a promising therapeutic approach [53].

Along the same line, Luo et al. also recently reported that proliferative ECSCs and quiescent MCSCs in breast cancer display different sensitivities to inhibitors of glycolysis and redox metabolism. Metabolic or oxidative stress promotes the transition of MCSCs with low levels of ROS to ECSCs with high levels of ROS. This transition depends on the AMPK-HIF1α pathway and is reversed by N-acetylcysteine. Moreover, silencing of expression of the gene encoding nuclear factor erythroid 2-like 2 (NRF2) or suppression of downstream thioredoxin and glutathione antioxidant pathways result in ECSCs sensitive to ROS-induced differentiation and cytotoxicity. However, both MCSCs and ECSCs are eliminated by co-inhibition of glycolysis and thioredoxin and glutathione pathways. This co-inhibition abolishes tumor-initiating potential, tumor growth, and metastasis [54]. The CSC phenotype is glycolytic in in vitro experiments, given the non-physiological concentrations of oxygen and glucose, whereas directly after cells are isolated from patients or after the first passage in culture CSCs depend on OXPHOS [52]. The upregulation of the glucose transporter Glut3 results in increased production of GSCs indicating how the high-grade glioblastomas, which are endowed with a high metabolic plasticity, survive in glucose-poor environments [55].

Metabolism as a therapeutic target for CSC
Several pathways which regulate metabolism and autophagy of CSCs, are targeted for the treatment of cancer (Table 2 and Fig. 2). Anti-CSC therapies causing a deficiencies in energy and materials impairing CSC survival and propagation establish the basis of the future therapies. The following paragraphs provide a brief preview of these therapeutic target and the compounds that influence metabolism and autophagy of CSCs.

Mitochondrial metabolism
As mentioned above, mitochondria play a key role in the responses to oxidative stress, energy status changes, and apoptotic stimuli and are also involved in the regulation of stemness and differentiation of CSCs [59]. Several pathways that promote anaerobic and aerobic energy metabolism of CSCs have been evaluated as targets for the treatment of cancer (Fig. 2).

OXPHOS inhibitors
Various compounds that inhibit oxidative metabolism result in sensitization of CSCs to chemotherapies, leading to their eradication. This has been demonstrated in a model of PDAC. KRAS mutations are known to be a driver event of PDAC, but targeting mutant KRAS has proved challenging. Using a KRAS-inducible mouse model, Viale et al. demonstrated that a subpopulation of cells with CSC features survives KRAS-ablation therapy and induces tumor relapse [87]. Transcriptomic and metabolic analyses of surviving cells demonstrated a strong expression of genes driving mitochondrial function and lysosomal and autophagic activity as well as a robust dependence on mitochondrial respiration and a decreased dependence on glycolysis for cellular energetics. Importantly, these cells depend on OXPHOS for survival.
| Metabolism-based strategies | Compound | Mechanism of action | CSC or tumor type | Reference |
|-----------------------------|----------|---------------------|------------------|-----------|
| Glycolysis inhibition       | 2-Deoxy-D-glucose | Glycolysis inhibitor | Breast CSCs | [21] |
|                             | 3-BP     | Glycolysis inhibitor | Glioblastoma CSCs, PDACs | [56] |
|                             | DCA      | Metabolic shift from glycolysis to OXPHOS | GBM cells | [57] |
| Inhibition of mitochondrial respiration | Metformin | Complex I inhibitor | Pancreatic CSCs, CSCs of HT29 cell line derived from colorectal cancer | [32, 58] |
|                             | Phenformin | Complex I inhibitor | Lung CSCs | [59–62] |
|                             | Rotenone | Complex I inhibitor | Breast CSCs | [59–62] |
|                             | Antimycin-A | Complex III inhibitor | Lung CSCs | [59–62] |
|                             | Bedaquiline | Complex III inhibitor | Breast CSCs | [59–62] |
|                             | Oligomycin | Complex V inhibitor | Breast CSCs | [63] |
| Salinomycin analogs         | Salinomycin analogs | Lysosomal iron sequestration | Breast CSCs | [63] |
|                             | Salinomycin analogs | Impairs autophagic flux | Breast CSCs | [64] |
|                             | Salinomycin analogs | Interference with ABC transporters | Breast, AML, lung, gastric, osteosarcoma, colorectal, pancreatic and prostate CSCs | [65] |
|                             | Salinomycin analogs | Activation of the Wnt/β-catenin signaling pathway | | |
| 188Re-Liposome               | 188Re-Liposome | Mitophagy inhibitor | Ovarian CSCs | [66] |
| Doxycycline                 | Doxycycline | Mitochondrial biogenesis inhibitor and inducer of apoptosis | Breast and cervical CSCs | [67, 68] |
| XCT-790                     | XCT-790 | ETC uncoupler, mitochondrial biogenesis inhibitor, inhibitor of ERRα-PGC-1 signaling pathway | Breast CSCs | [31] |
| Mdivi-1                     | Mdivi-1 | Fission inhibitor, inhibitor of assembly of Drp1 and its GTPase activity | Breast CSC, brain tumor initiating cells | [69, 70] |
| Redox homeostasis and antioxidant signaling | Zaprinast | Inhibition of glutathione biosynthesis, glutaminase inhibitor | Non-small lung and glutamine-addicted pancreatic cancer cell lines | [30, 59, 71] |
|                             | BPTES 968 | Neutralizer of ROS-induced NRF2 activity, STAT3 signaling pathway inhibitor, inhibitor of the NRF2 and NF-κB pathways | Ovarian and prostate CSCs, triple-negative breast cancers, leukemia stem-like cells | [72–76] |
|                             | BSO      | Neutralizer of ROS-induced NRF2 activity, STAT3 signaling pathway inhibitor, inhibitor of the NRF2 and NF-κB pathways | Ovarian and prostate CSCs, triple-negative breast cancers, leukemia stem-like cells | [72–76] |
|                             | Apigenin | Neutralizer of ROS-induced NRF2 activity, STAT3 signaling pathway inhibitor, inhibitor of the NRF2 and NF-κB pathways | Ovarian and prostate CSCs, triple-negative breast cancers, leukemia stem-like cells | [72–76] |
|                             | ATRA     | Neutralizer of ROS-induced NRF2 activity, STAT3 signaling pathway inhibitor, inhibitor of the NRF2 and NF-κB pathways | Ovarian and prostate CSCs, triple-negative breast cancers, leukemia stem-like cells | [72–76] |
|                             | Brusatol | Neutralizer of ROS-induced NRF2 activity, STAT3 signaling pathway inhibitor, inhibitor of the NRF2 and NF-κB pathways | Ovarian and prostate CSCs, triple-negative breast cancers, leukemia stem-like cells | [72–76] |
|                             | Disulfiram | Neutralizer of ROS-induced NRF2 activity, STAT3 signaling pathway inhibitor, inhibitor of the NRF2 and NF-κB pathways | Ovarian and prostate CSCs, triple-negative breast cancers, leukemia stem-like cells | [72–76] |
|                             | Trigonelline | Neutralizer of ROS-induced NRF2 activity, STAT3 signaling pathway inhibitor, inhibitor of the NRF2 and NF-κB pathways | Ovarian and prostate CSCs, triple-negative breast cancers, leukemia stem-like cells | [72–76] |
| Lipid metabolism            | 2M14NQ | Blocks CD36 activity and fatty acid uptake | Glioblastoma CSCs | [77] |
|                             | Saraphen A | Inhibitor of ACC | Breast CSCs | [78–80] |
|                             | Chloroquine | Inhibition of autophagy | Breast CSCs | [15, 64] |
|                             | TVB-2640 | FASN inhibitor | Breast CSCs | [70] |
|                             | MF-438 | SCD-1 inhibitor, inhibitor of FAO | Lung CSCs, liver cancer, glioblastoma and AML cells | [81, 82] |
|                             | SSI-4 | SCD-1 inhibitor, inhibitor of FAO | Lung CSCs, liver cancer, glioblastoma and AML cells | [81, 82] |
|                             | A939572 | SCD-1 inhibitor, inhibitor of FAO | Lung CSCs, liver cancer, glioblastoma and AML cells | [81, 82] |
|                             | Etomoxir | SCD-1 inhibitor, inhibitor of FAO | Lung CSCs, liver cancer, glioblastoma and AML cells | [81, 82] |
|                             | ST1326 | SCD-1 inhibitor, inhibitor of FAO | Lung CSCs, liver cancer, glioblastoma and AML cells | [81, 82] |
|                             | Avocatin B | SCD-1 inhibitor, inhibitor of FAO | Lung CSCs, liver cancer, glioblastoma and AML cells | [81, 82] |
|                             | Emodin | SCD-1 inhibitor, inhibitor of FAO | Lung CSCs, liver cancer, glioblastoma and AML cells | [81, 82] |
|                             | TVB-2640 | SCD-1 inhibitor, inhibitor of FAO | Lung CSCs, liver cancer, glioblastoma and AML cells | [81, 82] |
These CSC have high sensitivity to OXPHOS inhibitors and when OXPHOS inhibitors are combined with a targeted inhibitor of the KRAS pathway tumor recurrence is blocked [88]. However, metformin, which acts directly on the respiratory chain complex I in the mitochondria to inhibit OXPHOS and reduce mitochondrial ATP production (Fig. 2), was not enough to eliminate the CSC subpopulation [32]. This is possibly due to their intermediate glycolytic/respiratory phenotype and also to the heterogeneity and plasticity of PDAC cells. A previous study demonstrated that metformin increases ROS production in CSCs from PDAC cells and reduces their mitochondrial transmembrane potential. The AMPK/mTOR axis is not involved in the subsequent induction of lethal energy crisis in CSCs.

Interestingly, Kim et al. recently demonstrated that glutamine metabolism also plays an important role in regulation of the sensitivity of colorectal CSCs to metformin through a mechanism that depends on the AMPK/mTOR pathway. In the absence of glutamine, but not in low-glucose medium, CSCs from SW620 cells were sensitive to the CSC-suppressing effect of metformin with activation of AMPK and suppression of mTOR. A combination of metformin and glutaminase C inhibitor compound 968, an inhibitor of glutamine metabolism, suppressed proliferation of CSCs in SW620 cells and enhanced the effect of metformin alone in HT29 cells (Fig. 2). Thus, the sensitivity to metformin in this cell line is possibly due to activation of AMPK pathway.

Depletion of alanine serine cysteine transporter 2 (ASCT2), glutaminase 1, and c-MYC induced significant
CSC suppression. The compounds 968 and metformin also induced CSC elimination, and the activities were enhanced by silencing of ASCT2 and c-MYC. Thus, the effect of metformin on CSCs varies depending on the extent of activation of the AMPK/mTOR pathway and glutamine metabolism [58]. Consistent with a metabolic profile dominated by OXPHOS, ovarian CSCs undergo apoptosis upon inhibition of the mitochondrial respiratory chain by oligomycin, antimycin, rotenone, and metformin (Fig. 2).

CSCs have higher mitochondrial ROS production and elevated membrane potential as well as enhanced pentose phosphate pathway activity compared to normal counterparts. This metabolic characteristic is not representative of cells that privilege OXPHOS over glycolysis and may instead reflect the role of the pentose phosphate pathway in reloading scavenging enzymes [29]. In agreement with this, combined treatment with 5-fluorouracil, an inhibitor of thymidine synthesis, and a pharmacological inhibitor of OXPHOS abolishes drug resistance of colon cancer cells in culture and diminishes the expression of stem-like markers [89].

The efficacy of metformin has prompted efforts to repurpose available drugs to target CSCs [59]. Various FDA-approved antibiotics known to target the mitochondrial respiratory chain have been shown to selectively decrease CSC survival or proliferation (Fig. 2 and Table 2). Examples are antimycin A, a powerful complex III inhibitor that decreases lung spheroids; the anti-tuberculosis agent bedaquine (a complex V inhibitor) that inhibits mammosphere formation; oligomycin (another complex V inhibitor) that synergistically suppresses growth and motility of glioblastoma cell lines when combined with 2-deoxy-D-glucose (2-DG); and niclosamide, an anti-helminthic with OXPHOS uncoupling properties [90], that inhibits proliferation of CSCs from ovarian and breast cancers. Niclosamide also prevents the conversion of breast non-CSCs into CSCs induced by IL-6 [91]. Salinomycin also inhibits CSC formation in diverse cancer types [65]; OXPHOS is known to be inhibited by salinomycin [92]. Depletion of ATP levels and induction of mitophagy and mitoptosis are observed in cancer cells treated with salinomycin [93]. As a pleotropic compound that also interferes with Wnt signaling and ABC transporters, the antitumoral effect of salinomycin likely results from a combination of factors [65]. We recently demonstrated that salinomycin impairs autophagic flux [64] and kills CSCs by sequestering iron in lysosomes by ferroptosis [63] (Fig. 2).

The compound known as XCT-790 also prevents breast CSC survival and propagation. The rescue of the effect of XCT-790 by acetyl-L-carnitine (a mitochondrial fuel) indicates that mitochondria are the target of XCT-790 in CSCs [31]. XCT-790 is a strong and selective inverse agonist ligand of the estrogen-related receptor alpha (ERRα), which is a cofactor of peroxisome proliferator-activated receptor gamma co-activator (PGC-1α). PGC-1α is the master regulator of mitochondrial biogenesis and is essential for the activation of numerous nuclear transcription factors that control the transcription of many mitochondrial genes [94]. Independent of its inhibition of ERRα and mitochondrial biogenesis, XCT-790 is a potent mitochondrial electron transport chain uncoupler [95] (Fig. 2).

Numerous classes of FDA-approved antibiotics also inhibit mitochondrial biogenesis to eliminate CSCs [96]. These include the erythromycins, the tetracyclines, the glycyclelines, an anti-parasitic drug, and chloramphenicol. Efficacy was observed across eight different tumor types (breast, ductal carcinoma in situ, ovarian, prostate, lung, pancreatic, melanoma, and glioblastoma), suggesting that cancer can be treated as an infectious disease. Indeed, simultaneous inhibition of autophagy and treatment with antibiotics significantly reduces tumorigenic properties of cancer cells suggesting that this should be tested as a potential strategy for anticancer therapy [97]. However, continuous treatment with antibiotics for cancer therapy may not succeed due to induction of autophagy or a glycolytic shift.

Mitochondrial dynamics inhibitors
Mitochondria are dynamic organelles that often undergo fusion and fission events to sustain mitochondrial integrity and appropriate bioenergetics and spatial distribution. High levels of mitochondrial fission activity are associated with high proliferation and invasiveness in some cancer cells and with self-renewal and resistance to differentiation in some stem cells [98]. A specific inhibitor of the fission events, mDIV11, induced apoptosis in brain tumor initiating cells and inhibited tumor growth. mDIV11 is an inhibitor of dynamin-related protein 1 (DRP1), a mitochondrial fission protein, induces mitochondrial oxidative stress and reduces mitochondrial metabolism. CDK5-dependent DRP1 activation in brain tumor initiating cells stimulates mitochondrial fission preventing cell death and sustaining self-renewal and growth. DRP1 activation in brain tumor initiating cells correlates with poor glioblastoma patient survival [69]. Recently, Peiris-Pages et al. showed that mDIV11 prevents breast CSC survival and propagation [70].

Mitochondrial fission can produce an impaired daughter unit that is targeted by the autophagic machinery. Mitochondrial fusion, on the other hand, may serve to dilute impaired respiratory components and thereby prevent their removal. The inverse dependency of fusion and mitophagy on membrane potential allows these two processes to act in a complementary rather than competitive fashion on the daughter mitochondrion after a fission event [99]. Intraperitoneal delivery of the
nanomedicine 188Re-Liposome killed the CSCs-like cells in tumors with a degree of selectivity and switched metabolism from glycolysis to OXPHOS in an animal model of ovarian cancer [66] (Fig. 2). A study showed that dynamin 1-like-mediated mitochondrial fission induced by liensinine, a novel mitophagy inhibitor, sensitizes breast cancer cells to chemotherapy [100]. Recently, Chang et al. showed that mitophagy inhibitors such as liensinine and 188Re-Liposome abolish drug resistance in ovarian CSC-like cells [101].

Glycolysis inhibitors
Previous findings suggest that CSCs may be specifically dependent on a high glucose turnover; therefore, targeting the glycolytic pathway is a promising therapeutic approach. Zhou et al. demonstrated that the combination of a glycolysis inhibitor such as 3-bromopyruvate (3-BP) with standard therapeutic agents such as doxorubicin killed glioblastoma CSCs and inhibited tumor formation. This study suggests that stem-like cancer cells prefer a low oxygen microenvironment and actively utilize the glycolytic pathway [18]. Recently, Isayev et al. showed that treatment with 3-bromopyruvate almost completely blocked cell viability, self-renewal potential, NF-kB binding activity, and stem cell-related signaling and reverted gemcitabine resistance of CSCs from PDAC [56].

The switch from mitochondrial OXPHOS to cytoplasmic glycolysis is accompanied by development of the resistance to cell death in glioblastoma multiforme. This metabolic switch is accompanied by mitochondrial hyperpolarization. Michelakis et al. demonstrated that dichloroacetate (DCA), a small-molecule drug, induced a metabolic shift from glycolysis to OXPHOS, resulting in increased ROS, and induced apoptosis in CSC glioblastoma [57]. By inhibiting pyruvate dehydrogenase kinase (PDK), DCA activates PDH, increasing the ratio of glucose oxidation to glycolysis. On activation of PDH, however, pyruvate can be decarboxylated to acetyl-coenzyme A, enter the TCA cycle, and complete glucose oxidation in the mitochondrial matrix, generating up to 36 mol of ATP per glucose molecule in the presence of oxygen.

Targeting redox homeostasis and antioxidant signaling
Growing evidence supports a model for redox homeostasis in which the ROS-antioxidant interaction acts as a metabolic interface for signals derived from metabolism and from the environment. This interface regulates processes that allow cells to acclimate or, alternatively, to die. The efficacy of clinically used classical chemo and radiotherapy is due to high levels of intracellular ROS-induced cancer cell death. However, Yuan et al. recently reported that ROS generated from OXPHOS is essential in CSC activation [102], which promotes tumor development. This suggests that high levels of ROS may not eradicate CSCs.

CSCs are characterized by a finely regulated redox metabolism [103]. Glutathione plays an essential role in maintenance of stemness characteristics [104]. Glutathione synthesis may be inhibited either directly or indirectly by blocking glutamine synthetase (GS) or glutaminase enzymes (GLS). Several glutaminase inhibitors have been evaluated preclinically [30], including buthionine sulfoximine (BSO), 968, and bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) [59] (Fig. 2). Recently, zaprinast, an asthma medication was identified as a glutaminase inhibitor [71]. Depletion of glutathione and inhibition of thioredoxin reductase activity could also enhance radiation responses in human breast and pancreatic CSCs by a mechanism involving thiol-dependent oxidative stress. The following pharmacologically agents inhibit glutathione and thioredoxin metabolism: BSO; sulfasalazine (SSZ), an inhibitor of xc- (-) cysteine/glutamate antiporter; auranofin, a thioredoxin reductase inhibitor; and 2-AAPA, a GSH-reductase inhibitor. Combined inhibition of glutathione- and thioredoxin-dependent thiol metabolism can enhance responses of CSC to conventional therapies [105].

As mentioned above, NRF2 is a transcription factor that mediates the cytoprotective response to oxidative and electrophilic stress. Under the oxidative stress, NRF2 dissociates from its molecular inhibitor Kelch-like ECH-associating protein 1 (KEAP1) and translocates into the nucleus. There NRF2 binds to the antioxidant response element (ARE) of its target genes to induce their expression. NRF2 target genes include NADPH quinone oxidoreductase-1 (NQO-1) and aldo-keto reductase 1C1 and genes encoding glutathione generating enzymes and drug efflux transporters such as breast cancer resistance protein (BCRP). Recently, Kim et al. reported that all-trans retinoic acid (ATRA) inhibits NRF2 activation, suppresses ALDH1 expression, and leads to the attenuation of ovarian CSC-like properties [72] (Fig. 2).

In the presence of copper, administration of disulfiram, an approved anti-alcoholism drug, significantly downregulates ALDH1A1, CD44, and phospho-STAT3 levels. Disulfiram suppresses stem-like properties in triple-negative breast cancer by targeting the STAT3 signaling pathway [73]. Moreover, in leukemia stem-like cells, disulfiram and copper selectively activate the stress-related ROS-JNK pathway and simultaneously inactivate the NRF2 and NF-kB pathways [74]. Although disulfiram is now begin tested in phase III clinical trials, it is extremely unstable in blood. To increase disulfiram blood levels, a nanocarrier system of mPEG-PLGA/PCL has been used for the delivery [106].

Many other NRF2 inhibitors, including brusatol, apigenin, and trigonelline, have been identified (Fig. 2). Brusatol treatment suppresses NRF2 at the protein level, which results in enhanced intracellular ROS, sensitization
of mammospheres to taxol, and reduced anchorage-independent growth. However, further studies are needed to establish its in vivo action. Apigenin [75] and trigonelline [76] are transcriptional and translational NRF2 inhibitors, respectively, that were developed as adjuvants to chemotherapeutic drugs. Mechanistic analyses demonstrated that NRF2 silencing or treatment with trigonelline abolishes the ferroptosis resistance of KEAP1-deficient and cisplatin-resistant cancer cells to artesunate [76]. Paradoxically, some natural antioxidants, including sulforaphane, curcumin, resveratrol, oleanane triterpenoid, and carnosol, which all increase NRF2 expression levels, also have therapeutic potential. Readers interested in detailed discussion of this paradox should see recent reviews [59, 107].

**Lipid metabolism**

The role of lipid metabolism as a major source of energy and metabolic intermediates was recently demonstrated for processes implicated in transformation of normal cells into malignant cells and tumor progression [59]. Lipid metabolism is necessary for synthesis of membrane components. Fatty acids are broken down through mitochondria beta oxidation, which produces acetyl-coenzyme A (Ac-CoA) for anaplerosis. Citrate, a TCA cycle intermediate, can be used as a precursor for fatty acid synthesis and for NADPH production through the ATP citrate lyase (ACLY) (Fig. 2). Citrate is subsequently converted to acetyl-CoA and oxaloacetate in the cytoplasm. ACLY links glycolytic and lipidic metabolism. ACLY is overexpressed in cancer cells, and siRNA-mediated silencing of ACLY limits cancer cell proliferation and reduces the capacity of A549 lung cancer cells to form spheres [108]. ACLY inhibitors, previously developed for metabolic disorders, have recently attracted interest as promising anti-cancer agents [109]. Koerner et al. recently synthesized an emodin derivative and demonstrated that this novel ACLY inhibitor prevents proliferation of lung CSCs in vitro [85] (Fig. 2 and Table 2).

The committed step of fatty acid synthesis is the activation of acetyl-CoA to malonyl-CoA. This is an energy-consuming process catalyzed by acetyl-CoA carboxylase (ACC). The acetyl and malonyl groups are then coupled to the acyl-carrier protein domain of the multifunctional fatty acid synthase (FASN). Repeated condensations of acetyl groups generate the basic 16-carbon saturated palmitic acid. FASN activity is higher in adult murine neuronal stem and progenitor cells than in differentiated progeny [110]. Fatty acids are required for the production of phosphoglycerides, which, together with cholesterol, can be used for building cell membranes. Lipid droplets store triacyl glycerides and cholesteryl esters. Emerging data indicate that stored cholesteryl ester and accumulation of lipid droplets are correlated with tumorigenicity of CSCs derived from neurospheres and from ALDH+/CD133+ ovarian cancer cells [111] and colorectal cancer cells [112]. Thus, increased lipid storage in lipid droplets appears as a CSCs marker [112]. Lipids from extracellular sources can also be stored in lipid droplets. Thus, lipid metabolism is controlled by fatty acid synthesis and fatty acid oxidation (FAO) as well as by NADH, which is necessary for the production of ATP [113]. Lipolysis of lipids stored in lipid droplets was earlier considered to be solely carried out by cytosolic lipases. However, recent studies demonstrate that lipophagy (autophagic degradation of lipids by acidic lysosomes) serves as an alternate pathway for the degradation of lipid droplets [113]. Among target tested for CSC elimination, lipid metabolism is promising [59]. Several compounds that influence lipid metabolism have been tested preclinically (Fig. 2 and Table 2).

**Lipid uptake inhibition**

Lipid uptake can be inhibited by pharmacological inhibition or by antibody-mediated inhibition of the transporter fatty acid translocase CD36. Dietary lipid dependence of metastasis-initiating cells has recently been reported in melanoma and breast cancer. Inhibition of CD36, by specific antibodies, impairs metastasis [114]. Conversely, overexpression of CD36 significantly increases lymph node metastasis of oral squamous cell carcinoma cell lines with low metastatic potential [114]. Metastatic-initiating cells are also characterized by a distinct lipid metabolic signature related to fatty acid degradation, de novo lipogenesis, and lipid storage. CD36 is enriched in CSCs from glioblastoma and functionally distinguishes self-renewing cells. CD36 is co-expressed with integrin alpha 6 and CD133, previously described CSC markers, and CD36 reduction results in concomitant loss of integrin alpha 6 expression, self-renewal, and tumor initiation capacity. 2-Methylthio-1,4-naphthoquinone (2M14NQ), a unique sulfur-containing quinone, which inhibits CD36 activity, decreases self-renewal ability and induces apoptosis in glioblastoma CD133+ CSCs [77] (Fig. 2). CD36+ leukemia CSCs are enriched in gonadal adipose tissue and have elevated fatty acid uptake and beta oxidation [115]. Sulfosuccinimidyl olate, another CD36 inhibitory compound, decreases proliferation of chemoresistant leukemic CD36+/CD34+ stem cells [115]. The conversion of long chain fatty acids to fatty acyl-CoAs is catalyzed by the long-chain acyl-CoA synthetases (ACSL), which have been linked to carcinogenesis [116]. The ACSL inhibitor triacsin C is under investigation for the treatment of acyl-CoA synthetase-dependent tumors. However, there is no data available on the ACSL as a therapeutic target for CSC.

**Inhibition of lipogenesis and acyl-CoA synthetase lipid desaturation: FASN and stearoyl-CoA desaturase-1**

Results of a recent study support the theory of reactivation of de novo lipogenesis in solid tumors as part
of cancer metabolic reprogramming [113]. In invasive ductal carcinoma, acetyl CoA synthetase 2 (ACSS2), an enzyme that catalyzes the conversion of acetate to acetyl CoA, is overexpressed under hypoxic and lipid-depleted conditions. ACSS2 increases acetate consumption and thereby fatty acid biosynthesis in the harsh tumor microenvironment where there is a scarcity of alternate carbon sources for lipogenesis. Thus, targeting de novo lipogenesis and lipid desaturation could provide a selective mechanism to interfere with tumor growth.

A specific inhibitor of the first committed step of lipid biosynthesis catalyzed by ACC, the antifungal polyketide soraphen A, suppresses growth of breast CSCs [78] (Fig. 2). Mechanistic analysis suggests that the biotin carboxylase domain of the ACC, which is the soraphen A binding subunit dimerization site, may be an ideal target for ACC inhibitors with potential for use in cancer therapy.

**FASN inhibitors**

Given the involvement of the enzyme FASN in numerous tumor types, FASN inhibitors including C75, C93, epigallocatechin gallate, G28UCM, orlistat, Fasnall, GSK2194069, and GSK837149A have been evaluated in a mouse model of breast cancer [79]. Inhibition of FASN by cerulenin and of mevalonate pathways by atorvastatin prevents proliferation of CSCs in vitro [80] (Fig. 2 and Table 2). Numerous classes of ACC inhibitors have been evaluated in clinical trials for metabolic diseases (i.e., obesity and metabolic syndrome). Mechanistic analysis suggests that the biotin carboxylase domain of the ACC, which is the soraphen A binding subunit dimerization site, may be an ideal target for ACC inhibitors with potential for use in cancer therapy.

**SCD1 inhibitors**

A recent report using hyperspectral-stimulated Raman spectroscopic imaging and mass spectrometry analysis of extracted lipids showed that ovarian CSCs contain unusually high levels of unsaturated fatty acids (UFAs) and that UFAs are essential for the cells to retain stemness. These data suggest that increases in lipid unsaturation might be a general marker for CSCs in ovarian cancer and a new target for CSC-specific therapy [118]. Stearoyl-CoA desaturase-1 (SCD1), the most abundant desaturase, is expressed in lipogenic tissues and catalyzes the formation of double bonds at the ninth carbon atom of saturated fatty acids, leading to mono-unsaturated fatty acids. Using molecular approaches and chemical inhibitors such as CAY 10566 and SC26196, SCD1 was identified as the enzyme responsible for the increased desaturation in stem cells. Mechanistically, UFAs increase NF-κB activity, which upregulates expression of ALDH1 and SCD-1 mRNAs. Increased SCD1 in turn promotes UFA synthesis from saturated fatty acids, forming a positive feedback loop [118].

Two studies support the use of combination therapy with SCD1 inhibitors to achieve better control of cancer [81]. The first study reported that SCD1-mediated endoplasmic reticulum stress regulates liver tumor-initiating cells and sorafenib sensitivity. SCD1 inhibitors A939572 or SS1-4 alone or in combination with sorafenib thus have potential for treatment liver cancer [81]. In parallel, Pisnau et al. reported that co-treatment with cisplatin and the SCD1 inhibitor MF-438 decreases expression of lung CSCs markers, strongly synergizes in the inhibition of sphere formation, and induces apoptosis of lung CSCs [82] (Fig. 2 and Table 2). However, clinical utilization of SCD1 inhibitors for anti-cancer therapy should proceed with extreme caution. SCD1 is also involved in the regulation of inflammation and stress in various cell types, including β-cells, adipocytes, macrophages, endothelial cells, and myocytes.

Considering the established link between obesity and risk for many types of cancer, the observation that SCD1 deficiency protects mice against high-fat diet-induced obesity and hepatic steatosis [119] suggests that SCD1 inhibitors could serve the dual purpose of blunting tumor growth and preventing obesity and associated metabolic conditions. On the other hand, loss of SCD1 function is associated with the development of inflammatory diseases such as dermatitis, atherosclerosis, intestinal colitis, pancreatic β-cell dysfunction, and liver dysfunction [119]. Furthermore, SCD1 is highly expressed in the brain. Small-molecule inhibitors of SCD1 could cross the blood-brain barrier and interfere with the axon myelination process. Therefore, therapeutic strategies that target the re-activation of de novo lipogenesis of tumor tissues should take into consideration the risks of interference with active de novo lipogenesis in normal tissues.

**Inhibition of fatty acid oxidation**

FAO is a promising target for elimination of CSCs. Etomoxir, an inhibitor of the carnitine-dependent transporter CPT1 (also known as CPT1A), which inhibits the mitochondrial import of fatty acids mediated by the carnitine shuttle, decreases intracellular ATP levels as well as the viability and resistance to chemotherapy of glioblastoma and acute myeloid leukemia cells [120]. Silencing of Nanog or overexpression of cytochrome c oxidase subunit 6A and/or inhibition of FAO by etomoxir, sensitizes CSCs to sorafenib treatment. These data suggest that FAO inhibition or OXPHOS reestablishment to induce metabolic reprogramming of CSCs should
be a powerful therapy in hepatocellular carcinoma [121]. Unfortunately, the clinical development of etomoxir was terminated because of severe hepatotoxicity and hematopoietic stem cell exhaustion associated with treatment [120]. However, alternative FAO inhibitors are under investigation. For instance, the compound ST1326 strongly inhibits chemoresistance of leukemia cells with no effect on normal stem cells [83]. Additionally, another FAO inhibitor, avocatin B, which acts as a lipid that accumulates in mitochondria, eliminates CSCs from acute myeloid leukemia with no effect on normal blood stem cells [84] (Fig. 2 and Table 2).

**Concluding remarks**

It is now clear that the cancer is a heterogeneous disease and that metabolic heterogeneity and flexibility of tumor cells contributes to this heterogeneity. Location influences CSC metabolic status. In actively growing regions of the tumor and in the presence of adequate levels of oxygen, CSCs rely on glycolytic and/or oxidative metabolism. In nutrient-poor states, autophagy is activated as an alternative energy source. The catabolic glycolysis/oxidative phosphorylation and the anabolic gluconeogenesis pathway control glucose homeostasis. The metabolic adaptation of CSCs to the tumor microenvironment may provide an explanation for the metabolic differences observed in CSCs. However, further investigation are necessary to demonstrate the role of autophagy in plasticity and metabolic reprogramming. Current studies have revealed details of CSC metabolism in terms of redox state, lipid metabolism, and use of alternative fuels, such as amino acids or ketone bodies, identifying important vulnerabilities that could provide new therapeutic opportunities. However, to interrogate the metabolic traits of CSCs, metabolism must be analyzed directly after isolation from patients or after very few passages in culture to avoid artifactual switches in metabolic characteristics.

**Abbreviations**

2-DG: 2-deoxy-D-glucose; 2M14NQ: 2-methylthio-1,4-naphtoquinone; 3-BP: 3-bromopyruvate; ACC: Acetyl-CoA carboxylase; Ac-CoA: Acetyl-coenzyme A; ACLY: ATP citrate lyase; ACSL: Long-chain acyl-CoA synthetases; ACS52: Acetyl CoA synthetase 2; ALDH1:AS: Alddehyde dehydrogenase 1A3; AMPK: AMP-activated protein kinase; ARE: Antioxidant response element; ASCT2: Alanine serine cysteine transporter 2; ATP: Adenosine triphosphate; ATRA: All-trans retinoic acid; BCPR: Breast cancer resistance protein; BCSCs: Breast cancer stem cells; Bnpi3: Bcl-2/Adenovirus E1B interacting protein; 3 BPTE3: Bis-2-(S-phenylacetamido-1,3,4-thiadiazol-2-y) ethyl sulfide; BSO: L-buthionine-S,R-sulfoximine; CAFs: Cancer-associated fibroblasts; CPT1: Carnitine palmitoyltransferase; CS: Citrate synthase; CSC: Cancer stem cell; DCA: Dichloroacetate; DNMT: DNA methyltransferases; Doc: Doxycycline; DRP1: Dynamin-related protein 1; ECGS: Epithelial CSCs; EMT: Epithelial-mesenchymal transition; ERRA: Estrogen-related receptor alpha; F6P: Fructose-6-phosphate; FAO: Fatty acid oxidation; FASN: Fatty acid synthetase; FAT/CD36: Fatty acid translocase; FB1: Fructose-1,6-bisphosphatase; FOXO3A: Forkhead box 3A; G6PDH: Glucose-6-phosphate dehydrogenase; GBM: Glioblastoma; GCS: Gamma-glutamylcysteine synthetase; GDH: Glutamate dehydrogenase; GFAT: Glutamin-fructose-6-phosphate transaminase 1; GLS: Glutaminase; GLS1: Mitochondrial glutaminase; GLS2: Cytosolic isoform glutaminase; GLUT1, 2, 3, 4: Glucose transporter 1,2, 3,4; GS: Glutamine synthetase; GSC: Glioblastoma stem cells; GSH: Glutathione; HIF-1α: Hypoxia-inducible factor 1α; H2K: Hexokinase 2; HMG-CoAR: 3-hydroxy-3-methylglutaryl-Coenzyme A reductase; I/O: Mitochondrial complexes; JNK/Ap1: c-Jun N-terminal kinases/activator protein 1; KEAP1: Kelch-like ECH-associated protein 1; KLF4: Kruppel-like factor 4; LC3: Microtubule-associated Protein 1 Light Chain 3; LDH: Lactate dehydrogenase; MCT2/4: Monocarboxylate transporter 2/4; MitF: Mitochondrial; NADH: Nicotinamide adenine dinucleotide (reduced); NADPH: Nicotinamide adenine dinucleotide phosphate (reduced); NAMPT: Nicotinamide phosphoribosyltransferase; NANOg: Nanog Homeobox; NF-kB: Nuclear factor-kB; NMN: Nicotinamide mononucleotide; NQO-1: NADPH quinone oxidoreductase-1; NR2F2: Nuclear factor erythroid 2-related factor 2; OA: Oxaebacetate; OCT4: Octamer-binding transcription factor 4; OXPHOS: Oxidative phosphorylation; P: Phosphate (or phospho); PARPs: Poly (ADP-ribose) polymerases; PDAC: Pancreatic ductal adenocarcinoma; PDH: Pyruvate dehydrogenase; PD1: Pyruvate dehydrogenase kinase 1; PKKB: Phosphofructokinase/fructose bisphosphatase; PGC-1α: Peroxisome proliferator-activated receptor gamma co-activator; PHGDH: Phosphoglycerate dehydrogenase; PKM2: Pyruvate kinase isozyme M2; PGC-1α: Peroxisome proliferator-activated receptor gamma co-activator; NMN: Nicotinamide N-methyltransferase; NQO-1: NADPH: quinone oxidoreductase-1; NR2F2: Nuclear factor erythroid 2-related factor 2; OA: Oxalacetate; OCT4: Octamer-binding transcription factor 4; OXPHOS: Oxidative phosphorylation; P: Phosphate (or phospho); PARPs: Poly (ADP-ribose) polymerases; PDAC: Pancreatic ductal adenocarcinoma; PDH: Pyruvate dehydrogenase; PD1: Pyruvate dehydrogenase kinase 1; PKFB: Phosphofructokinase/fructose bisphosphatase; PGC-1α: Peroxisome proliferator-activated receptor gamma co-activator; PHGDH: Phosphoglycerate dehydrogenase; PKM2: Pyruvate kinase isozyme M2; PGC-1α: Peroxisome proliferator-activated receptor gamma co-activator; NMN: Nicotinamide N-methyltransferase; NQO-1: NADPH: quinone oxidoreductase-1; NR2F2: Nuclear factor erythroid 2-related factor 2; OA: Oxalacetate; OCT4: Octamer-binding transcription factor 4; OXPHOS: Oxidative phosphorylation; P: Phosphate (or phospho); PARPs: Poly (ADP-ribose) polymerases; PDAC: Pancreatic ductal adenocarcinoma; PDH: Pyruvate dehydrogenase; PD1: Pyruvate dehydrogenase kinase 1; PKFB: Phosphofructokinase/fructose bisphosphatase; PGC-1α: Peroxisome proliferator-activated receptor gamma co-activator; PHGDH: Phosphoglycerate dehydrogenase; PKM2: Pyruvate kinase isozyme M2; RHOA: Homolog family member; ROS: Reactive oxygen species; SAM: S-adenosyl methionine; SCID1: Stearyl-CoA desaturase-1; SFA: Saturated fatty acids; SIRTs: Siruins; SLCA1A3: Solute carrier family 1 member 5; SOX2: Sex determining region Y-box 2; S, SZ: Sulfasalazine; T: Tetracyclines; TCA: Tricarboxylic acid cycle; TGF-β: Transforming growth factor β; UFA: Unsaturated fatty acids.

**Acknowledgments**

We apologize for the omission of any primary citations.

**Authors’ contributions**

AH and MM have contributed equally to the writing process of this manuscript. MEH, AH, and MM drafted the manuscript. MEH and EC discussed, helped to design all figures and contributed to writing the review. All authors read and approved the final manuscript.

**Funding**

Supported in part by grants from INSERM, Université Paris Descartes-Sorbonne Paris Cité, and Comité de Paris de la ligue contre le cancer. Mouradi EL Hout thanks LASER association for funding.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

The authors declare that they consent for publication.
Competing interests
The authors declare that they have no competing interests.

Glossary
Electron transport chain
A series of transmembrane protein complexes, present on the inner membrane of mitochondria, that transfer electrons via redox reactions to the terminal electron acceptor oxygen, which is reduced by binding of protons to a water molecule. This generates a proton gradient that powers ATP synthase to produce ATP. Premature leakage of electrons to oxygen can lead to production of reactive oxygen species.

Glutaminolysis
The act of replenishing TCA cycle intermediates used for macromolecule biosynthesis.

Catabolism
The removal of internal metabolites, especially those resulting from the TCA cycle, to prevent their accumulation in the mitochondrial matrix.

Glutathione
A tripeptide (glutamate-cysteine-glycine) that acts as an important antioxidant. The reduced form of glutathione can react with H₂O₂ to form the oxidized form (GSSG).

Glutaminolysis
A series of biochemical reactions by which the glutamine is lysed to generate molecules such as CO₂, alanine, aspartate, citrate, glutamate, lactate, and pyruvate. When glycolytic energy production is low, glutamine, the most common amino acid in the plasma, serves as an additional energy source for tumor cells. Glutamine is also a nitrogen source for amino acids, hexosamines (amino sugars involved in the synthesis of glycosylated molecules), and nucleotides. In cancer cells, glutamine metabolism fuels the TCA cycle, fatty acid and nucleotide biosynthesis, and redox balance. Most cancer cells consume glutamine, and many tumors are thought to be addicted to glutamine [124]. This addiction results largely from the contribution of glutamine to anaplerosis [125].

Macroautophagy
Referred to here as autophagy, allows the orderly degradation of cellular components and recycling of amino acids, lipids, nucleic acids, and saccharides from intracellular nutrient stores. In this catabolic process, double-membranated vesicles called autophagosomes form around cellular cargo, including organelles, protein aggregates, and intracellular pathogens. After fusion of autophagosome with a lysosome, the cargo is degraded.

Nicotinamide adenine dinucleotide (NAD) metabolism
NAD acts as an electron and hydrogen acceptor during glycolysis, fatty acid oxidation, and the TCA cycle. NAD also serves as a coenzyme for oxidoreductases and dehydrogenases that generate ATP during nutrient degradation, playing a key role in cellular respiration. NAD and its phosphorylated and reduced forms, including NADP, NADH, and NADPH, are essential for cell metabolism activities. NAD most often functions in catabolic energy-generating reactions where it is reduced to NADH. The phosphorylated form, NADPH, participates in anabolic reactions, such as the synthesis of fatty acids and cholesterol. In addition to its function in oxidative phosphorylation and redox reactions, NAD is a substrate for evolutionarily conserved NAD cleavage enzymes such as poly (ADP-ribose) polymerases (PARPs), sirtuins (SIRTs), and cADP-ribose synthases such as CD38 and CD157.

Author details
1 Institut Necker-Enfants Malades (INEM), Inserm U1151-CNRS UMR 8253, F-75993 Paris, France. 2 Université Paris Descartes-Sorbonne Paris Cité, F-75993 Paris, France.

Received: 20 August 2019 Accepted: 26 December 2019
Published online: 06 February 2020

References
1. Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(2):113.
2. Snyder V, Reed-Newman TC, Arnold I, Thomas SM, Anant S. Cancer stem cell metabolism and potential therapeutic targets. Front Oncol. 2018;8:203.
3. Mowers EE, Sharifi MN, Macleod KF. Functions of autophagy in the tumor microenvironment and cancer metastasis. FEBS J. 2018;285(10):1751–66.
4. Poillet-Perez L, White E. Role of tumor and host autophagy in cancer metabolism. Genes Dev. 2019;33(11–12):610–9.
5. Poillet-Perez L, Xi X, Zhao L, Yang Y, Shap DW, Hu ZS, et al. Autophagy maintains tumor growth through circulating arginine. Nature. 2018;563(7732):569–73.
6. Palm W, Thompson CB. Nutrient acquisition strategies of mammalian cells. Nature. 2017;546(7657):234–42.
7. Lysiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017;27(11):863–75.
8. Smith AG, Macleod KF. Autophagy, cancer stem cells and drug resistance. J Pathol. 2018.
9. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.
10. Cordier-Bussat M, Thiibert C, Sujobert P, Genestier L, Fontaine E, Billaud M. Even the Warburg effect can be oxidized: metabolic cooperation and tumor development. Med Sci (Paris). 2018;34(8–9):701–8.
11. Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Ceconi F, et al. Molecular definitions of autophagy and related processes. EMBO J. 2017;36(13):1811–36.
12. Boya P, Codogno P, Rodriguez-Muela N. Autophagy in stem cells: repair, remodelling and metabolic reprogramming. Development. 2018;145(4).
13. Cufi S, Vazquez-Martín A, Olivares-Ferrares C, Martín-Castillo B, Vellon L, Menendez JA. Autophagy positively regulates the CD34(+) CD45(-) low breast cancer stem-like phenotype. Cell Cycle. 2011;10(22):3871–85.
14. Gong C, Baux C, Tonelli G, Yue W, Delomene C, Nicolas V, et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene. 2013;32(18):2261–72. 72e1–11.
15. Vera-Ramirez L, Vodnala SK, Nini P, Hunter KW, Green JE. Autophagy promotes the survival of dormant breast cancer cells and mammalian tumor recurrence. Nat Commun. 2018;9(1):1944.
16. Sharif T, Martell E, Dai C, Kennedy BE, Murphy P, Clements DR, et al. Autophagic homeostasis is required for the pluri-potency of cancer stem cells. Autophagy. 2017;13(2):264–84.
17. Nazio F, Bordi M, Cianfarini V, Locatelli F, Ceconi F, Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ. 2019;26(4):690–702.
18. Zhou Y, Zhou Y, Shingu T, Feng L, Chen Z, Ogawa T, Mihara K, et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem. 2011;286(37):32843–53.
19. Liu PP, Liao J, Tang ZI, Wu WJ, Yang J, Zeng ZL, et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ. 2014;21(11):124–35.
20. Alvero AB, Montagna MK, Suriu NU, Izzo WD, Graham E, Mor G. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget. 2014;5(18):8703–15.
21. Ciavardelli D, Rossi C, Bancardi D, Volpe S, Consolavo A, Zucchielli M, et al. Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death Dis. 2014;5:e1336.
22. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, et al. Loss of FBP1 by inhibitors. Oncotarget. 2014;5(18):8703–15.
23. Viale A, Pettazzoni P, Lysiotis CA, Ying H, Sanchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;524(7563):628–32.
24. Feng W, Gentles AJ, Nair RV, Huang M, Lin Y, Lee CY, et al. Targeting unique metabolic properties of breast tumor initiating cells. Stem Cells. 2014;32(7):1734–45.
25. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res. 2012;72(6):1438–48.
26. Chen KY, Liu X, Bu P, Lin CS, Rakhilin N, Locasale JW, et al. A metabolic signature of colon cancer initiating cells. Proc Natl Acad Sci U S A. 2014;111(16):5790–6.
27. Chae YC, Kim JH. Cancer stem cell metabolism: target for cancer therapy. Cell Death Differ. 2018;25(7):319–26.
28. Famie G, Sotgia F, Lisanti MP. High mitochondrial mass identifies a subpopulation of stem-like cancer cells that are chemo-resistant. Oncotarget. 2015;6(31):30472–86.
29. Pasto A, Bellino C, Filotto G, Ciminale V, Silei-Benussi M, Guzzo G, et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 2014;5(12):4305–19.
30. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorey MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458(7239):780–3.
31. De Luca A, Fiorillo M, Peiris-Pages M, Ozsvari B, Smith DL, Sanchez-Alvarez R, et al. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget. 2015;6(17):14777–95.
32. Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenen M, et al. MYC/PGC-1alpha balance determines the metabolic phenotype and plasticity of pancreatic Cancer stem cells. Cell Metab. 2015;22(4):590–605.
33. Bonuccelli G, Sotgia F, Lisanti MP. Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways. Aging (Albany NY). 2018;10(8):1867–83.
34. Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera O, Kossel E, et al. Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target. Stem Cells. 2012;30(7):1327–36.
35. Xiang L, Semenza GL. Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy. Adv Cancer Res. 2019;141:175–212.
36. Samanta D, Park Y, Andrabi SA, Shelton LM, Gilles DM, Semenza GL. PHGDH expression is required for mitochondrial redox homeostasis, breast Cancer stem cell maintenance, and lung metastasis. Cancer Res. 2016;76(15):4430–42.
37. Lucena-Cacace A, Umeda M, Navas LE, Carnero A. NAMPT as a stem-like/progenitor cells interferes with their maintenance. Autophagy. 2013;7(10):1593–15.
38. Lu Y, Kvitkovicz J, Liu Y, Tech K, Frady LN, Su YT, et al. Chemosensitivity of IDH1-mutated Glomas due to an impairment in PARP1-mediated DNA repair. Cancer Res. 2017;77(7):1709–18.
39. Chen ZT, Zhao W, Qu S, Li L, Lu XG, Su F, et al. PARP-1 promotes autophagy via the AMPK/mTOR pathway in CNE-2 human nasopharyngeal carcinoma cells following ionizing radiation, while inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells. Mol Med Rep. 2015;12(1):1868–76.
40. Zhang DX, Zhang JP, Hu JY, Huang YS. The potential regulatory roles of NAD(+) and its metabolism in autophagy. Metabolism. 2016;65(4):454–62.
41. Aguilera E, Marin de mas I, Zodda E, Marin S, MoriTh F, Selivanov V, et al. Metabolic reprogramming and dependencies associated with epithelial Cancer stem cells independent of the epithelial-Mesenchymal transition program. Stem Cells. 2016;34(5):1163–76.
42. El Hout M, Dos Santos L, Hamar A, Mephrour P. A promising new approach to cancer therapy: targeting iron metabolism in cancer stem cells. Semin Cancer Biol. 2018;53:125–38.
43. Recalcati S, Gammella E, Cairo G. Dysregulation of iron metabolism in cancer stem cells. Free Radic Biol Med. 2018.
44. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou QY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.
45. Lee SY, Jeon HM, Ju MK, Kim CH, Yoon G, Han SI, et al. Wnt/signal regulation regulates cytochrome C oxidase and glucose metabolism. Cancer Res. 2012;72(4):3607–17.
46. Aspiria PP, Lunt SY, Varemo L, Vergnes L, Gozo M, Beach JA, et al. Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab. 2014;2:21.
47. Luo M, Brooks M, Wicha MS. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des. 2015;21(10):1301–10.
48. Peiris-Pages M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer stem cell metabolism. Breast Cancer Res. 2016;18(1):55.
49. Mao P, Joshi KJ, Li J, Kim SH, Li P, Santana-Santos L, et al. Mesenchymal glioma stem cells are maintained by activated glycogenic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A. 2013;110(21):8644–9.
50. Luo M, Shang L, Brooks MD, Jiaoge E, Zhu Y, Buschhaus JM, et al. Targeting Breast Cancer stem cell state equilibrium through modulation of redox signaling. Cell Metab. 2018;28(1):86–96.
51. Fivashana WA, Wu Q, Hitolmi M, Rahim N, Kim Y, Sloan AE, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 2013;16(10):1373–82.
52. Isayev O, Rausch V, Bauer N, Liu L, Fan P, Zhang Y, et al. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget. 2014;5(3):5177–89.
53. Michalakos ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31ra4.
54. Kim JH, Lee KY, Seo Y, Kwon JH, Yoon JP, Kang JY, et al. Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. Sci Rep. 2018;8(1):409.
55. Jagust P, de Luan-Delgado B, Parejo-Alonso B, Sancho P. Metabolism-based therapeutic strategies targeting Cancer stem cells. Front Pharmacol. 2019;10:203.
56. Yeh CT, Su CL, Huang CY, Lin JK, Lee WH, Chang PM, et al. A preclinical evaluation of antimiR-40 as a potential antilung cancer stem cell agent. Evid Based Complement Alternat Med. 2013;2013:910451.
57. Fiorillo M, Lamb R, Tanowitz HB, Cappello AR, Martinez-Outschoorn UE, Sotgia F, et al. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging (Albany NY). 2016;8(8):1593–607.
58. Kennedy CR, Tilkens SB, Gnan H, Garner JA, Or PM, Chan AM. Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions. Cancer Lett. 2013;336(2):299–306.
59. Ma TT, Hamai A, Hienzsch A, Caneque T, Muller S, Wicinski J, et al. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem. 2017;9(10):1025–33.
60. Yue W, Hamai A, Tonelli G, Baux C, Nicolas V, Tharinger H, et al. Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance. Autophagy. 2013;9(5):714–29.
61. Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658.
62. Shen YA, Lan RL, Chang CH, Lin LT, He CL, Chen PH, et al. Intraperitoneal (188)Re-liposome delivery switches ovarian cancer metabolism from glycolysis to oxidative phosphorylation and effectively controls ovarian tumour growth in mice. Radiother Oncol. 2016;119(2):282–90.
63. Scatena C, Roncella M, Di Paola A, Aretini P, Menicagli M, Fanelli G, et al. Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces Cancer stem cells (CSCs) in early breast Cancer patients: a clinical pilot study. Front Oncol. 2018;8:452.
64. Yang B, Lu Y, Zhang A, Zhou A, Zhang L, Zhang L, et al. Doxycycline induces apoptosis and inhibits proliferation and invasion of human cervical carcinoma stem cells. PLoS One. 2015;10(6):e0129138.
65. Xie Q, Wu Q, Horbinski CM, Flavahan WA, Yang K, Zhou W, et al. Mitochondrial control by DRIP1 in brain tumor initiating cells. Nat Neurosci. 2015;18(4):501–10.
66. Peiris-Pages M, Bonuccelli G, Sotgia F, Lisanti MP. Mitochondrial fission as a driver of stemness in tumor cells: mDIVI inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling. Oncotarget. 2018;9(17):13254–75.
71. Elhammali A, Ippolito JE, Collins L, Crowley J, Marasa J, Pwncna-Worms D. A high-throughput fluorometric assay for 2-hydroxylguatate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov. 2014;4(7):828–39.

72. Kim D, Choi BH, Ryoo K, Kwak MK. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: Inhibitory role of all-trans retinoic acid in ALDH-NRF2 signaling. Cell Death Dis. 2018;9(9):896.

73. Kim YJ, Kim YJ, Lee N, Oh E, Sung D, Cho TM, et al. Dsulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells. Biochem Biophys Res Commun. 2017;484(6):1069–75.

74. Xu B, Wang S, Li R, Chen K, He L, Deng M, et al. Dsulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-INK and inhibition of NF-kappaB and Nrf2. Cell Death Dis. 2017;8(3):e2797.

75. Erdogan S, Turkkel K, Serttas R, Erdogan Z. The natural flavonoid apigenin sensitizes CD44(+) prostate cancer stem cells to cisplatin therapy. Biomed Pharmacother. 2017;88:210–7.

76. Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017;11:254–62.

77. Hale JS, Ovios B, Sinyuk M, Alvarado AG, Hitomi M, Stoltz K, et al. Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem Cells. 2014;32(7):1746–58.

78. Corominas-Faja B, Cuyas E, Gmuruzzo J, Bosch-Barrera J, Leis O, Martin AG, et al. Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget. 2014;5(18):9308–16.

79. Alvarawah Y, Hughes P, Lissieille D, Carlson DA, Darr NR, Jordan JL, et al. Fasnall, a selective FASIN inhibitor, shows potent anti-tumor activity in the MMVT-Neu model of HER2(+) breast Cancer. Cell Chem Biol. 2016;23(6):678–88.

80. Yasumoto Y, Miyazaki H, Vaidyan LK, Kagawa Y, Ebrahimi M, Yamamoto Y, et al. Blockade of Stearoyl- CoA desaturase regulates soroifen resistance via modulation of ER stress-induced differentiation. J Hepatol. 2017;67(3):579–90.

81. Pisanu ME, Noto A, De Vitis C, Morrone S, Scognamiglio G, Botti G, et al. Inhibition of fatty acid synthase decreases expression of Stemness markers in glioma stem cells. PLoS One. 2016;11(1):e0147717.

82. Ma M, Lau EYT, Leung DHW, Lo J, Ho NPY, Cheng LKW, et al. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. J Cell Sci. 2016;129(3):925–40.

83. Lee EA, Angka L, Rota SG, Hanlon T, Mitchell A, Hurren R, et al. Targeting mitochondria with Avocatin B induces selective leukemia cell death. Cancer Res. 2015;75(12):4788–94.

84. Koerner SK, Hanai J, Bal S, Jermann FE, Oki M, Komaba C, et al. Design and synthesis of emodin derivatives as novel inhibitors of APT-citrare isoy. Eur J Med Chem. 2017;126:920–8.

85. Wang L, Li P, Hu W, Xia Y, Hu C, Liu L, et al. CD44(+)CD24(-) subset of cancer cells is sensitive to Avocatin B-induced selective leukemia cell death. Cancer Med. 2017;6(8):1259–79.

86. Song W, Tang Z, Lei T, Wen X, Wang G, Zhang D, et al. Stable loading and delivery of soybean oil with mPEG-PLA/PCL microsized nanoparticles for tumor therapy. Nanomedicine. 2016;12(2):377–86.

87. Wollnik C, Zarkovic N, Saso L. Controversy about pharmacological modulation of Nrf2 for cancer therapy. Redox Biol. 2017;12:727–32.

88. Hanai J, Doro N, Seth P, Suiklmat V. ATP citrate lyase knockdown impacts cancer stem cells in vitro. Cell Death Dis. 2013;4:e696.

89. Granchi C. ATP citrate lyase (ACLY) inhibitors: an anti-cancer strategy at the crossroads of glucose and lipid metabolism. Eur J Med Chem. 2018;157:726–91.

90. Knobloch M, Braun SM, Zurkirchen L, von Schoultz C, Zamboni N, Arauzo-Bravo MI, et al. Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis. Nature. 2013;493(7431):226–30.

91. Sun P, Xia S, Lal B, Shi X, Yang KS, Watkins PA, et al. Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity. BMC Cancer. 2014;14:401.

92. Tirinato L, Liberale C, Di Franco S, Candelloro P, Benfante A, La Rocca R, et al. Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging. Stem Cells. 2015;33(3):635–44.

93. Menn M, Peters JM, Dutta M, Patterson AD. Lipid metabolism and lipogenesis in cancer. Biochem Biophys Res Commun. 2018;504(3):582–9.

94. Pascual G, Augustinova A, Mejerta S, Martin M, Castellanos A, Attolino CS, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541(7635):841–5.

95. Ye H, Adare B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19(1):23–37.

96. Young PA, Senkal CE, Suchanek AL, Grevengoed TJ, Lin DD, Zhao L, et al. Long-chain acyl-CoA synthetase 1 interacts with key proteins that activate and direct fatty acids into niche hepatic pathways. J Biol Chem. 2018;293(4):16724–40.

97. Corominas-Faja B, Vellon L, Cuyas E, Buxo M, Martin-Castillo B, Serra D, et al. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histol Histopathol. 2017;32(7):887–98.
118. Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 2017;20(3):303–14 e5.

119. Liu X, Strable MS, Ntambi JM. Stearoyl CoA desaturase 1: role in cellular inflammation and stress. Adv Nutr. 2011;2(1):15–22.

120. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013;12(11):829–46.

121. Chen CL, Uthaya Kumar DB, Punj V, Xu J, Sher L, Tahara SM, et al. NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell Metab. 2016;23(1):206–19.

122. Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology. 2015;26(1):68–78.

123. Fiorillo M, Peiris-Pages M, Sanchez-Alvarez R, Bartella L, Di Donna L, Dolce V, et al. Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, rho-GDI-signalling and mitochondrial metabolism. Biochim Biophys Acta Bioenerg. 2018;1859(9):984–96.

124. Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(12):773.

125. Kralj AS, Christofk HR. Rethinking glutamine addiction. Nat Cell Biol. 2015;17(12):1515–7.

126. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witbiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8(23):3984–4001.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.